Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.

Name: Αlpha¹ Rigor Record — Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Item: Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Rating: 88
Author: Αlpha¹

Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 4 high issues for “Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

CitationsUnresolved reference ×4−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: lowEngine: 7.39.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.
The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 1 reported mean was read, and its group size is not stated where the value is printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
Declared data/code links were not checked for liveness or content.

Problems surfaced3 types

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper reports a well-conducted adaptive platform trial with strong ethical approvals, detailed methods, and transparent reporting. The main weakness is incomplete reporting of randomization details and blinding, which are minor but notable for a clinical trial.

All three reviewers classified the study as interventional; no disagreement. The evaluation covered the full text, with N/A for animal-related and cell-line criteria. The statistics verification could not recompute any tests due to lack of test statistics/df, so statistical correctness is not independently confirmed.

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Reporting

Eight Dimensions8 pass

The introduction cites prior clinical studies (TROPION-PanTumor01, pooled analysis) and the I-SPY2 trial, acknowledging strengths and limitations. The rationale for testing Dato-DXd in early-stage breast cancer is clearly linked to its mechanism and activity in metastatic disease. Limitations of prior work are addressed through the adaptive trial design and dynamic control.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 70% conf

The scientific premise is established with citations of prior work, but the limitations of prior research are only partially addressed.

Evidence

paraphrase[Introduction, paragraph 1]

“In the phase 1 TROPION-PanTumor01 study that included patients with metastatic non-small cell lung cancer, hormone receptor (HR) + / human epidermal growth factor receptor 2 (HER2) − breast cancer and TNBC, Dato-DXd showed promising clinical activity with an overall response rate of 31.8% in heavily pretreated patients with TNBC, 26.8% in HR + /HER2 − breast cancer and 40% in patients with TNBC who had not received prior treatment with a topoisomerase inhibitor-based ADC.”

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing prior research on Dato-DXd, the I-SPY2 trial, and the rationale for the I-SPY2.2 design.

Evidence

direct quote[Introduction, paragraph 3]